Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where E. Angevin is active.

Publication


Featured researches published by E. Angevin.


Cancer Discovery | 2017

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

C. Massard; Stefan Michiels; Charles Ferté; Marie-Cécile Le Deley; Ludovic Lacroix; Antoine Hollebecque; Loic Verlingue; Ecaterina Ileana; Silvia Rosellini; Samy Ammari; Maud Ngo-Camus; Rastislav Bahleda; Anas Gazzah; Andrea Varga; Sophie Postel-Vinay; Yohann Loriot; Caroline Even; Ingrid Breuskin; Nathalie Auger; Bastien Job; Thierry de Baere; Frederic Deschamps; Philippe Vielh; Jean-Yves Scoazec; Vladimir Lazar; Catherine Richon; Vincent Ribrag; Eric Deutsch; E. Angevin; Gilles Vassal

High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as measured by the percentage of patients presenting progression-free survival (PFS) on matched therapy (PFS2) 1.3-fold longer than the PFS on prior therapy (PFS1). A total of 1,035 adult patients were included, and a biopsy was performed in 948. An actionable molecular alteration was identified in 411 of 843 patients with a molecular portrait. A total of 199 patients were treated with a targeted therapy matched to a genomic alteration. The PFS2/PFS1 ratio was >1.3 in 33% of the patients (63/193). Objective responses were observed in 22 of 194 patients (11%; 95% CI, 7%-17%), and median overall survival was 11.9 months (95% CI, 9.5-14.3 months).Significance: This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit. Cancer Discov; 7(6); 586-95. ©2017 AACR.See related commentary by Schram and Hyman, p. 552This article is highlighted in the In This Issue feature, p. 539.


Annals of Oncology | 2012

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

C. Gomez-Roca; Ludovic Lacroix; C. Massard; T. de Baere; F. Deschamps; R. Pramod; Rastislav Bahleda; Eric Deutsch; C. Bourgier; E. Angevin; Vladimir Lazar; Vincent Ribrag; Serge Koscielny; L. Chami; Nathalie Lassau; Clarisse Dromain; Caroline Robert; E. Routier; J-P. Armand

BACKGROUND Sequential tumour biopsies are of potential interest for the rational development of molecular targeted therapies. PATIENTS AND METHODS From June 2004 to July 2009, 186 patients participated in 14 phase I clinical trials in which sequential tumour biopsies (13 trials) and/or sequential normal skin biopsies (6 trials) were optional. All patients had to sign an independent informed consent for the biopsies. RESULTS Tumour biopsies were proposed to 155 patients and 130 (84%) signed the consent while normal skin biopsies were proposed to 70 patients and 57 (81%) signed the consent. Tumour biopsies could not be carried out in 41 (31%) of the 130 consenting patients. Tumour biopsies were collected at baseline in 33 patients, at baseline and under treatment in 56 patients. Tumour biopsies were obtained using an 18-gauge needle, under ultrasound or computed tomography guidance. Only nine minor complications were recorded. Most tumour biopsy samples collected were intended for ancillary molecular studies including protein or gene expression analysis, comparative genomic hybridization array or DNA sequencing. According to the results available, 70% of the biopsy samples met the quality criteria of each study and were suitable for ancillary studies. CONCLUSIONS In our experience, the majority of the patients accepted skin biopsies as well as tumour biopsies. Sequential tumour and skin biopsies are feasible and safe during early-phase clinical trials, even when patients are exposed to anti-angiogenic agents. The real scientific value of such biopsies for dose selection in phase I trials has yet to be established.BACKGROUND Sequential tumour biopsies are of potential interest for the rational development of molecular targeted therapies. PATIENTS AND METHODS From June 2004 to July 2009, 186 patients participated in 14 phase I clinical trials in which sequential tumour biopsies (13 trials) and/or sequential normal skin biopsies (6 trials) were optional. All patients had to sign an independent informed consent for the biopsies. RESULTS Tumour biopsies were proposed to 155 patients and 130 (84%) signed the consent while normal skin biopsies were proposed to 70 patients and 57 (81%) signed the consent. Tumour biopsies could not be carried out in 41 (31%) of the 130 consenting patients. Tumour biopsies were collected at baseline in 33 patients, at baseline and under treatment in 56 patients. Tumour biopsies were obtained using an 18-gauge needle, under ultrasound or computed tomography guidance. Only nine minor complications were recorded. Most tumour biopsy samples collected were intended for ancillary molecular studies including protein or gene expression analysis, comparative genomic hybridizartion array or DNA sequencing. According to the results available, 70% of the biopsy samples met the quality criteria of each study and were suitable for ancillary studies. CONCLUSIONS In our experience, the majority of the patients accepted skin biopsies as well as tumour biopsies. Sequential tumour and skin biopsies are feasible and safe during early-phase clinical trials, even when patients are exposed to anti-angiogenic agents. The real scientific value of such biopsies for dose selection in phase I trials has yet to be established.


Annals of Oncology | 2015

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

Eric Deutsch; C. Le Pechoux; L. Faivre; S. Rivera; Y. Tao; J.P. Pignon; M. Angokai; R. Bahleda; Désirée Deandreis; E. Angevin; Christophe Hennequin; Benjamin Besse; A. Levy

BACKGROUND This phase I study evaluated the safety and efficacy of the oral mTOR inhibitor everolimus in combination with thoracic radiotherapy followed by consolidation chemotherapy in locally advanced or oligometastatic untreated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Everolimus dose was escalated in incremental steps [sequential cohorts of three patients until the occurrence of dose-limiting toxicity (DLT)] and administered orally weekly (weekly group: dose of 10, 20 or 50 mg) or daily (daily group: 2.5, 5 or 10 mg), 1 week before, and during radiotherapy until 3.5 weeks after the end of radiotherapy. Two cycles of chemotherapy (cisplatin-navelbine) were administrated 4.5 weeks after the end of radiotherapy. RESULTS Twenty-six patients were included in two centers, 56% had adenocarcinoma and 84% had stage III disease. In the weekly group (12 assessable patients), everolimus could be administered safely up to the maximum planned weekly dose of 50 mg; however, one patient experienced a DLT of interstitial pneumonitis at the weekly dose level of 20 mg. In the daily group (9 assessable patients): one DLT of interstitial pneumonitis with a fatal outcome was observed at the daily dose level of 2.5 mg; two other DLTs (one grade 3 esophagitis and one bilateral interstitial pneumonitis) were found at the daily dose level of 5 mg. Overall there were five patients with G3-4 interstitial pneumonitis related to treatment. Among 22 assessable patients for response, there were 9 (41%) partial response and 7 (32%) stable disease. At a median follow-up of 29 months, the 2-year overall survival and progression-free survival actuarial rates were 31% and 12%, respectively. CONCLUSION In previously untreated and unselected NSCLC patients, the recommended phase II dose of everolimus in combination with thoracic radiotherapy is 50 mg/week. Pulmonary toxicity is of concern and should be carefully monitored to establish the potential role of mTOR inhibitor with concomitant radiotherapy. EUDRACT N 2007-001698-27.BACKGROUND This phase I study evaluated the safety and efficacy of the oral mTOR inhibitor everolimus in combination with thoracic radiotherapy followed by consolidation chemotherapy in locally advanced or oligometastatic untreated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Everolimus dose was escalated in incremental steps [sequential cohorts of three patients until the occurrence of dose-limiting toxicity (DLT)] and administered orally weekly (weekly group: dose of 10, 20 or 50 mg) or daily (daily group: 2.5, 5 or 10 mg), 1 week before, and during radiotherapy until 3.5 weeks after the end of radiotherapy. Two cycles of chemotherapy (cisplatin-navelbine) were administrated 4.5 weeks after the end of radiotherapy. RESULTS Twenty-six patients were included in two centers, 56% had adenocarcinoma and 84% had stage III disease. In the weekly group (12 assessable patients), everolimus could be administered safely up to the maximum planned weekly dose of 50 mg; however, one patient experienced a DLT of interstitial pneumonitis at the weekly dose level of 20 mg. In the daily group (9 assessable patients): one DLT of interstitial pneumonitis with a fatal outcome was observed at the daily dose level of 2.5 mg; two other DLTs (one grade 3 esophagitis and one bilateral interstitial pneumonitis) were found at the daily dose level of 5 mg. Overall there were five patients with G3-4 interstitial pneumonitis related to treatment. Among 22 assessable patients for response, there were 9 (41%) partial response and 7 (32%) stable disease. At a median follow-up of 29 months, the 2-year overall survival and progression-free survival actuarial rates were 31% and 12%, respectively. CONCLUSION In previously untreated and unselected NSCLC patients, the recommended phase II dose of everolimus in combination with thoracic radiotherapy is 50 mg/week. Pulmonary toxicity is of concern and should be carefully monitored to establish the potential role of mTOR inhibitor with concomitant radiotherapy. EUDRACT N 2007-001698-27.


Annals of Oncology | 2016

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Sophie Postel-Vinay; Y. Boursin; C. Massard; Antoine Hollebecque; Ecaterina Ileana; M. Chiron; J. Jung; J. S. Lee; Z. Balogh; Julien Adam; Philippe Vielh; E. Angevin; Ludovic Lacroix

BACKGROUND Molecular tumour profiling technologies have become increasingly important in the era of precision medicine, but their routine use is limited by their accessibility, cost, and tumour material availability. It is therefore crucial to assess their relative added value to optimize the sequence and combination of such technologies. PATIENTS AND METHODS Within the MOSCATO-01 trial, we investigated the added value of whole exome sequencing (WES) in patients that did not present any molecular abnormality on array comparative genomic hybridization (aCGH) and targeted gene panel sequencing (TGPS) using cancer specific panels. The pathogenicity potential and actionability of mutations detected on WES was assessed. RESULTS Among 420 patients enrolled between December 2011 and December 2013, 283 (67%) patients were analysed for both TGPS and aCGH. The tumour sample of 25 (8.8%) of them presented a flat (or low-dynamic) aCGH profile and no pathogenic mutation on TGPS. We selected the first eligible 10 samples-corresponding to a heterogeneous cohort of different tumour types-to perform WES. This allowed identifying eight mutations of interest in two patients: FGFR3, PDGFRB, and CREBBP missense single-nucleotide variants (SNVs) in an urothelial carcinoma; FGFR2, FBXW7, TP53, and MLH1 missense SNVs as well as an ATM frameshift mutation in a squamous cell carcinoma of the tongue. The FGFR3 alteration had been previously described as an actionable activating mutation and might have resulted in treatment by an FGFR inhibitor. CREBBP and ATM alterations might also have suggested a therapeutic orientation towards epigenetic modifiers and ataxia-telangectasia and Rad3-related inhibitors, respectively. CONCLUSION The therapeutic added value of performing WES on tumour samples that do not harbour any genetic abnormality on TGPS and aCGH might be limited and variable according to the histotype. Alternative techniques, including RNASeq and methylome analysis, might be more informative in selected cases.


European Journal of Cancer | 2016

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Jean-Marie Michot; C. Bigenwald; Stéphane Champiat; M. Collins; F. Carbonnel; Sophie Postel-Vinay; A. Berdelou; A. Varga; R. Bahleda; Antoine Hollebecque; C. Massard; A. Fuerea; Vincent Ribrag; Anas Gazzah; Jean-Pierre Armand; N. Amellal; E. Angevin; N. Noel; C. Boutros; C. Mateus; Caroline Robert; Aurelien Marabelle; Olivier Lambotte


Annals of Oncology | 2016

Identification of new prognostic factors in phase I patients treated by immunotherapy

F. Bigot; E. Castanon Alvarez; A. Hollebecque; Ana T. Carmona; S. Postel-Vinay; E. Angevin; J-P. Armand; V. Ribrag; Sandrine Aspeslagh; A. Varga; Rastislav Bahleda; A. Gazzah; C. Bonnet; J-M. Michot; A. Marabelle; J-C. Soria; C. Massard


European Journal of Cancer | 2017

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

E. Angevin; Gianluca Spitaleri; Jordi Rodon; Katia Fiorella Dotti; Nicolas Isambert; Stefania Salvagni; Victor Moreno; Sylvie Assadourian; Corinne Gomez; Marzia Harnois; Antoine Hollebecque; Analia Azaro; Alice Hervieu; Karim Rihawi; Filippo De Marinis


European Journal of Cancer | 2017

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

Antoine Hollebecque; Rastislav Bahleda; Laura Faivre; J. Adam; Vianney Poinsignon; Angelo Paci; C. Gomez-Roca; Jean Christophe Thery; M.C. Le Deley; A. Varga; Anas Gazzah; E. Ileana; M. Gharib; E. Angevin; K. Malekzadeh; C. Massard; Jean-Philippe Spano


European Journal of Cancer | 2014

219 Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients: A novel approach to treat HPV related malignancies?

Eric Deutsch; Antonin Levy; R. Mazeron; Anas Gazzah; E. Angevin; Vincent Ribrag; Rastilav Balheda; A. Varga; Catherine Lhommé; Christine Haie-Meder


Investigational New Drugs | 2018

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors

Rastislav Bahleda; Marie-Cécile Le Deley; Apexa Bernard; Shalini Chaturvedi; Michael J. Hanley; Audrey Poterie; Anas Gazzah; A. Varga; Mehdi Touat; Eric Deutsch; C. Massard; Helgi van de Velde; Antoine Hollebecque; M. Sallansonnet-Froment; Damien Ricard; Hervé Taillia; E. Angevin; Vincent Ribrag; Jean-Charles Soria

Collaboration


Dive into the E. Angevin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Varga

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anas Gazzah

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vincent Ribrag

Université Paris-Saclay

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Marabelle

University of Paris-Sud

View shared research outputs
Top Co-Authors

Avatar

J-C. Soria

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

Loic Verlingue

Université Paris-Saclay

View shared research outputs
Researchain Logo
Decentralizing Knowledge